Waiving Clinical Studies and Accelerating Drug Development for Kinase Inhibitor (KI) Drugs

Explore how Simcyp delivered benefits during multiple stages of the drug cycle, with these information-rich case studies from Certara.

Read now for insights into:

US FDA’s citing of ibrutinib (Imbruvica) example as the best practice for use of PBPK (Simcyp)
Simcyp Simulator’s ability to predict outcomes for a compound with complex, time-dependent,
non-linear PK
Simcyp PBPK simulations relied on for CYP DDI predictions over clinical results
Simcyp’s use in supporting approval of first-in-kind and only treatment for rare pediatric disease
Examples of how >10 clinical pharmacology studies were replaced by PBPK simulations in final drug label
New capabilities for Simcyp; predicting interpatient variability in patients with co-morbidities

Read the Case Study

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Certara to store and process the information submitted to provide you the content requested. They are subject to Certara's Terms and Conditions.

Please complete all required fields to access the content!

Future-Ready Pharmacovigilance: Integrating AI With FDA's EDSTP Guidelines

Join IQVIA’s esteemed panel of experts for an in-depth discussion on how AI can meet and exceed these new expectations. This webinar delves into the intersection of regulatory frameworks and technological innovation, offering insights into the future of PV and how organizations can navigate this transformative field. Key takeaways include:

Accelerating Biologics Development With Strategies For Success

The biologics market is growing rapidly, unlocking exciting opportunities but also presenting significant challenges. Developers are undergoing pressure to accelerate the delivery of innovative therapies while addressing complex regulatory demands, navigating demanding clinical trial phases, efficiently scaling production, and maintaining quality. In this webinar, industry experts will share practical strategies and real-world examples to help you navigate these challenges. Key takeaways:

A New Era of Participant Payment Services

Financial burdens are cited as one of the main barriers to clinical trial recruitment and retention, with traditional methods proving unreliable, complicated and slow. For trial sites and sponsors, the administration burden can be overwhelming, especially on a global scale. Discover how IQVIA’s Participant Payment service is transforming the participant payment landscape, simplifying the process and driving clinical trial success, by offering: